William Blair Analysts Raise Earnings Estimates for Harrow

Harrow, Inc. (NASDAQ:HROW) – Stock analysts at William Blair raised their Q3 2025 earnings per share estimates for Harrow in a research report issued to clients and investors on Tuesday, August 12th. William Blair analyst L. Hanbury-Brown now anticipates that the company will post earnings per share of $0.13 for the quarter, up from their previous estimate of $0.08. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Harrow’s current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow’s Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.22 EPS and FY2026 earnings at $1.37 EPS.

Other equities research analysts also recently issued research reports about the stock. Cantor Fitzgerald started coverage on shares of Harrow in a research note on Friday, July 11th. They set an “overweight” rating and a $76.00 price target on the stock. HC Wainwright set a $64.00 target price on Harrow and gave the stock a “buy” rating in a report on Wednesday. Finally, BTIG Research reiterated a “buy” rating and issued a $63.00 target price (up previously from $62.00) on shares of Harrow in a report on Thursday. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, Harrow currently has a consensus rating of “Buy” and a consensus target price of $64.67.

Harrow Stock Performance

NASDAQ:HROW opened at $38.82 on Friday. The stock has a market capitalization of $1.44 billion, a P/E ratio of -155.28 and a beta of 0.41. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The stock has a 50-day moving average price of $33.18 and a 200 day moving average price of $28.91. The company has a current ratio of 0.62, a quick ratio of 0.85 and a debt-to-equity ratio of 0.78.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. The firm had revenue of $63.74 million during the quarter, compared to analysts’ expectations of $64.23 million.

Institutional Investors Weigh In On Harrow

A number of institutional investors and hedge funds have recently modified their holdings of the business. Braidwell LP lifted its stake in shares of Harrow by 5.5% during the 1st quarter. Braidwell LP now owns 956,839 shares of the company’s stock worth $25,452,000 after acquiring an additional 49,800 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Harrow by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 810,803 shares of the company’s stock worth $24,765,000 after acquiring an additional 36,724 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its stake in shares of Harrow by 6.7% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 664,714 shares of the company’s stock worth $22,301,000 after acquiring an additional 41,896 shares during the last quarter. Marshall Wace LLP lifted its stake in shares of Harrow by 31.5% during the 2nd quarter. Marshall Wace LLP now owns 564,876 shares of the company’s stock worth $17,251,000 after acquiring an additional 135,202 shares during the last quarter. Finally, Voya Investment Management LLC lifted its stake in shares of Harrow by 4,035.5% during the 1st quarter. Voya Investment Management LLC now owns 381,461 shares of the company’s stock worth $10,147,000 after acquiring an additional 372,237 shares during the last quarter. 72.76% of the stock is owned by institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.